Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CEL-SCI Corporation (NYSE American: CVM) SEC filings, offering detailed insight into the company’s clinical stage cancer immunotherapy business and capital structure. As a Colorado corporation filing under Commission file number 001-11889, CEL-SCI uses periodic and current reports to describe its development of Multikine (Leukocyte Interleukin, Injection), financing activities, and corporate governance arrangements.
Investors can review Form 10-K and Form 10-Q filings for discussions of research and development expenses, going concern disclosures, and updates on the Multikine clinical program in head and neck cancer. These reports typically describe the company’s strategy of boosting the immune system before surgery, radiotherapy and chemotherapy have damaged it, and summarize the status of the completed Phase 3 study and planned 212-patient confirmatory Registration Study.
Form 8-K current reports are particularly important for CEL-SCI. Recent 8-K filings disclose material definitive agreements for best-efforts public offerings of common stock with ThinkEquity LLC as placement agent, including the number of shares issued, offering prices, gross proceeds, and intended use of proceeds to fund the continued development of Multikine, general corporate purposes, and working capital. Other 8-Ks report amendments and revisions to the company’s Shareholder Rights Agreement, including extensions of its expiration date and related governance terms.
Users can also reference registration statements on Form S-3 cited in these filings, which support CEL-SCI’s shelf offerings. Together, these documents help clarify how the company finances its operations, manages shareholder rights, and describes the risks associated with its clinical stage status, including going concern language noted by its independent auditors. Stock Titan’s tools can surface the most relevant sections, summarize lengthy filings, and make it easier to track new CVM filings as they are posted to EDGAR, including any future Forms 4 reporting insider transactions.
Cel-Sci Corp. (CVM) Form 4 filing discloses that Chief Executive Officer and Director Geert R. Kersten purchased 2,292 shares of common stock on 06/30/2025 at a price of $2.29 per share. Following the transaction, Kersten directly holds 43,638 shares. No derivative security activity was reported. The filing was signed on 07/01/2025 and represents a single-person submission under Section 16 reporting requirements.